Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion
MK-1084-012
Phase 3 small_molecule active
Quick answer
Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion for KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active